
Abbott Launches Updated Oncodetect MRD Test to Track Residual Cancer
Abbott has launched a new version of its Oncodetect blood test for monitoring residual cancer during and after treatment. The test uses whole-genome sequencing to track more tumour-specific DNA…














































































